Matches 1 - 50 out of 384 1 2 3 4 5 6 7 8 >


Match Document Document Title
US20070218138 Pharmaceutical Compositions  
Forms and formulations of VX-950 and uses thereof.
US20160244497 FGF21 MUTANTS AND USES THEREOF  
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for...
US20160199435 METHODS FOR PREVENTING OR TREATING METABOLIC SYNDROME  
The invention provides methods of preventing or treating metabolic syndrome in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic...
US20150231204 PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAME  
The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.
US20140296139 MITOCHONDRIAL-DERIVED PEPTIDE MOTS3 REGULATES METABOLISM AND CELL SURVIVAL  
MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
US20120083442 MYOSTATIN BINDING AGENTS  
The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one...
US20110039766 METHODS FOR PREVENTING OR TREATING METABOLIC SYNDROME  
The invention provides methods of preventing or treating metabolic syndrome in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic...
US20100136105 PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS  
The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present...
US20100113363 Use of GLP-1 Peptides  
GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
US20090170778 PYY Agonists and Uses Thereof  
The invention provides PYY3-36 variants and pegylated derivatives thereof and compositions and methods useful in the treatment of conditions modulated by an NPY Y2 receptor agonist.
US20090149387 Use of GLP-1 Peptides  
GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
US20080102124 Modified Human Growth Hormone  
Modified growth hormone polypeptide and uses thereof are provided.
US20070027085 Microencapsulation and sustained release of biologically active polypeptides  
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically...
US20050143303 Intranasal administration of glucose-regulating peptides  
Pharmaceutical compositions and methods are described comprising at least one glucose-regulating peptide, such as amylin, glucagon-like peptide-1 (GLP), pramlintide or exendin-4 and one or more...
US20160228503 Compositions and Formulations for Prevention and Treatment of Diabetes and Obesity, and Methods of Production and Use Thereof in Glucose and Caloric Control  
Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides,...
US20150274634 COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF  
Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or...
US20140315795 Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types  
The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic...
US20140256620 METHODS FOR REDUCING CD36 EXPRESSION  
The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an...
US20140213512 Method of Treating or Ameliorating Type 1 Diabetes Using FGF21  
Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia,...
US20130338063 Methods and Compositions for the Treatment of Gastrointestinal Disorders  
Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders,...
US20130143796 CHIMERIC POLYPEPTIDES AND USES THEREOF  
The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating...
US20070244048 Neuromedin U receptor agonists and uses thereof  
Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed.
US20070021346 N-terminally modified GLP-1 receptor modulators  
The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are...
US20060188496 Intranasal administration of active agents to the central nervous system  
A method for delivering a polypeptide to the central nervous system of a mammal is provided. The method involves attaching the polypeptide to an antibody or an antibody fragment and administering...
US20150174266 APROTININ POLYPEPTIDES FOR TRANSPORTING A COMPOUND ACROSS THE BLOOD-BRAIN BARRIER  
The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as...
US20140005096 METHODS OF TREATING INFLAMMATION  
Disclosed herein, in certain embodiments, are peptides for use in inhibiting the interactions of PF4 and RANTES. Further disclosed herein, are methods for treating an inflammatory disease,...
US20110105389 Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same  
The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone...
US20100317570 Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor  
The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one...
US20070167374 Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)  
In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30...
US20060121035 Methods for treating diabetes  
Methods for treating diabetes by administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta (TGF-β) superfamily of structurally-related growth factors (e.g.,...
US20050287180 Phospholipid compositions and methods for their preparation and use  
The present invention provides compositions that comprise a phospholipid component (that contains one or more phospholipids) and a pharmaceutically acceptable fluid carrier, where the phospholipid...
US20160175411 INFANT NUTRITION WITH PROTEASE INHIBITOR  
Provided is an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and/or prevention of...
US20160058874 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY  
Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system...
US20150094257 USE OF NUTRITIONAL COMPOSITIONS FOR PREVENTING DISORDERS  
The present invention relates to a method for preventing and/or treating visceral adiposity and/or to alter body fat distribution by administering a certain nutritional composition to a human...
US20140328794 ALBUMIN FUSION PROTEINS  
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors...
US20140066368 Methods For Affecting Body Composition  
Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight be reduced, maintained or even increased; however, the body fat is reduced or body fat gain...
US20120052069 FGF21 MUTANTS AND USES THEREOF  
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for...
US20100129374 Mammalian Cell Membrane Proteins; Related Reagents  
The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells,...
US20080299166 NOVEL BIOMATERIALS, THEIR PREPARATION AND USE  
The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an...
US20080176804 Methods for Affecting Body Composition  
Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat...
US20070173455 Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)  
In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30...
US20060154871 Peptides  
The amino acid sequence of several peptides present in Colostrinin is disclosed. These peptides are useful, inter alia, in the treatment of disorders of the immune system and the central nervous...
US20160220635 GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF  
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of...
US20140243259 GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF  
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of...
US20100113332 METHOD OF TREATING AN INFLAMMATORY DISEASE BY DOUBLE STRANDED RIBONUCLEIC ACID  
What is disclosed is the use of a formulation comprising double stranded ribonucleic acid (dsRNA) in the manufacture of a medicament for treating an inflammatory disease in a mammal and inhibiting...
US20090291886 TRANSMUCOSAL DELIVERY OF PEPTIDES AND PROTEINS  
Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the...
US20090028814 HIGH MOLECULAR WEIGHT MEDICINE-CONTAINING PREPARATION IN POWDER FORM FOR ADMINISTRATION THROUGH MUCOSA  
A preparation in powder form for administration through mucosa, comprising a medicine of high molecular weight and a cationic polymer is disclosed. By adding a cationic polymer (in particular, a...
US20090011995 PRODUCTION OF A SOLUBLE NATIVE FORM OF RECOMBINANT PROTEIN BY THE SIGNAL SEQUENCE AND SECRETIONAL ENHANCER  
The present invention is drawn to a method for enhancing secretional efficiency of a heterologous protein using a secretional enhancer consisting of a modified signal sequence which comprises the...
US20070054851 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases  
The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with...
US20070010450 Methods and compositions for the treatment of gastrointestinal disorders  
Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders,...

Matches 1 - 50 out of 384 1 2 3 4 5 6 7 8 >